Theravance Biopharma (TBPH) AI Stock Analysis

• Market Cap: $557.51M
• Dividend Yield: N/A
• Average Volume (3M): 295.54K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: 6.11%
• EPS Growth: -37.79%
• Country: US
• Employees: 97
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 50,001,330
• 10 Day Avg. Volume: 267,626
• 30 Day Avg. Volume: 295,542
• PEG Ratio: 0.16
• Price to Book (P/B): 1.87
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.40
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 2.36
• Enterprise Value/Gross Profit: 9.22
• Enterprise Value/Ebitda: -4.16
• 1Y Price Target: $19.00
• Price Target Upside: 70.40% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 57 Neutral
• Price Target: $11.00 ▼(-1.35%Downside)

Theravance Biopharma's stock score reflects a mixed outlook. Financial stabilization and strategic advancements, such as the milestone payment from Viatris, are positive. However, ongoing profitability challenges and valuation concerns limit the score. Technical indicators suggest potential for upward momentum, but increased operating expenses and pending litigation remain risks.

Positive Factors

Financial Milestones

TBPH is eligible to receive up to $37.5M in sales-based milestones and 14-20% tiered royalties on Yupelri net sales in China.

Partnership Benefits

Viatris' substantial commercial presence in China and its 4,200-strong sales force are expected to benefit Yupelri and TBPH.

Product Approval

Yupelri has been approved for COPD in China, ahead of expectations, leading to a milestone payment for TBPH.

Negative Factors

Market Competition

Currently available treatments for nOH-MSA have poor efficacy and safety profiles, highlighting the challenges in the market.

Treatment Limitations

Up to 70% of patients with currently available options are inadequately controlled, with around 50% developing treatment-limiting supine hypertension.

Theravance Biopharma Business Overview & Revenue Model

Company Description

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

How the Company Makes Money

Theravance Biopharma generates revenue through the development and commercialization of pharmaceutical products. The company earns money from product sales, collaborative agreements, and licensing arrangements. Key revenue streams include sales of its FDA-approved medications and income from strategic partnerships with larger pharmaceutical companies for the co-development and commercialization of its drug candidates. These partnerships often entail upfront payments, milestone payments based on development or regulatory achievements, and royalties on sales of co-developed products. Theravance Biopharma's financial performance is also influenced by its investment in research and development, aiming to expand its pipeline and bring new therapies to market.

Theravance Biopharma Financial Statement Overview

Summary

Theravance Biopharma is stabilizing financially with improved cash flow and revenue growth, but profitability challenges persist. The balance sheet shows a healthier equity position, but net losses continue.

Income Statement

The company has shown some revenue growth, with a 13.65% increase from 2023 to 2024 and a 1.38% growth from 2024 to TTM (Trailing-Twelve-Months). However, consistent negative net income and EBIT indicate ongoing operational challenges. The gross profit margin is strong at 100% for TTM, but the net profit margin remains negative due to high operating expenses relative to revenue.

Balance Sheet

The company has improved its equity position, moving from negative to positive stockholders' equity, which is a positive sign. The debt-to-equity ratio is 0.29 for TTM, indicating manageable leverage. However, the consistent negative net income has impacted return on equity, which remains negative.

Cash Flow

The company has significantly improved its free cash flow, turning positive in TTM from negative in previous years. The operating cash flow to net income ratio is negative due to negative net income, but free cash flow has improved due to better management of operating expenses and capital expenditures.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	65.27M	64.38M	57.42M	51.35M	55.31M	71.86M
Gross Profit	65.27M	64.38M	57.42M	44.76M	48.02M	-189.10M
EBITDA	-42.30M	-38.45M	-42.66M	-79.86M	-249.39M	-294.00M
Net Income	-58.33M	-56.42M	-55.19M	-92.82M	-199.43M	-278.02M
Balance Sheet
Total Assets	343.58M	354.16M	382.00M	607.40M	374.82M	469.06M
Cash, Cash Equivalents and Short-Term Investments	130.85M	88.35M	102.43M	327.48M	173.47M	292.94M
Total Debt	48.16M	49.82M	49.16M	74.12M	652.08M	647.06M
Total Liabilities	177.60M	178.62M	169.00M	165.60M	713.39M	772.81M
Stockholders Equity	165.98M	175.54M	213.00M	441.80M	-338.57M	-303.75M
Cash Flow
Free Cash Flow	32.28M	-11.87M	-29.48M	-187.56M	-211.26M	-257.02M
Operating Cash Flow	32.53M	-11.54M	-27.00M	-186.99M	-207.86M	-250.40M
Investing Cash Flow	25.89M	12.28M	-32.70M	1.15B	124.49M	10.72M
Financing Cash Flow	-1.64M	-2.50M	-198.93M	-758.81M	91.86M	263.08M

Theravance Biopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.15
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TBPH, the sentiment is Positive. The current price of 11.15 is above the 20-day moving average (MA) of 10.81, above the 50-day MA of 10.11, and above the 200-day MA of 9.33, indicating a bullish trend. The MACD of 0.28 indicates Positive momentum. The RSI at 62.38 is Neutral, neither overbought nor oversold. The STOCH value of 60.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TBPH.

Theravance Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MGTX	63 Neutral	$603.54M	―	-216.14%	―	203.23%	-80.71%
TBPH	57 Neutral	$557.51M	―	-31.46%	―	6.11%	-37.79%
SAGE	55 Neutral	$576.12M	―	-63.53%	―	-47.94%	30.94%
CAPR	52 Neutral	$468.51M	―	-75.39%	―	-35.92%	-62.11%
Sector *	49 Neutral	AU$2.49B	4.37	-64.25%	2.83%	36.51%	13.14%
KROS	46 Neutral	$546.28M	―	0.71%	―	91657.69%	97.21%
MNMD	40 Neutral	$541.72M	―	-37.07%	―	―	26.24%

Theravance Biopharma Corporate Events

Theravance Biopharma Gains Milestone Payment from Viatris

On June 26, 2025, Theravance Biopharma announced that Viatris secured regulatory approval from China’s NMPA for YUPELRI® (revefenacin) inhalation solution, marking it as the first once-daily nebulized LAMA for COPD maintenance treatment in China. This approval triggers a $7.5 million milestone payment from Viatris to Theravance, expected in Q3 2025, and positions Theravance for further sales-based milestones and royalties, enhancing its financial standing without incurring commercial costs in China.

The most recent analyst rating on (TBPH) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.

Theravance Biopharma Settles Patent Litigation with Eugia

On June 5, 2025, Theravance Biopharma and Mylan entered into a Settlement Agreement with Eugia Pharma to resolve ongoing patent litigation concerning the YUPELRI® inhalation solution. The agreement allows Eugia to manufacture and market a generic version of YUPELRI® in the U.S. starting April 23, 2039, pending review by the U.S. Department of Justice and the Federal Trade Commission, while litigation continues against other ANDA filers.

The most recent analyst rating on (TBPH) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.

Theravance Biopharma Sells Trelegy Royalty Interest to GSK

On May 30, 2025, Theravance Biopharma entered into an agreement with GlaxoSmithKline (GSK) to sell its remaining royalty interest in Trelegy Ellipta for $225 million. This transaction, part of the company’s strategic efforts to maximize shareholder value, follows a previous sale of Trelegy royalty interests in 2022 for $1.1 billion. The deal underscores Theravance Biopharma’s strategy to monetize its assets while retaining rights to potential milestone payments from Royalty Pharma.

The most recent analyst rating on (TBPH) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.

Theravance Biopharma Holds 2025 Annual General Meeting

At the 2025 Annual General Meeting held on May 19, Theravance Biopharma shareholders elected Class II directors and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Additionally, a non-binding advisory resolution on executive compensation was approved, reflecting shareholder support for the company’s leadership and financial oversight.

The most recent analyst rating on (TBPH) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.